Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 6/20 | 1.00 |
| ▸ | FUCA1 | P04066 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371513 | 1.00 | GBA1 (1.00) | GBA1FUCA1LMNAAPPSI | |
| SCHEMBL371514 | 1.00 | GBA1 (1.00) | GBA1FUCA1LMNAAPPSI | |
| SCHEMBL247045 | 1.00 | GBA1 (1.00) | GBA1FUCA1LMNAAPPSI | |
| SCHEMBL29885626 | 1.00 | GBA1 (1.00) | GBA1FUCA1LMNAAPPSI | |
| SCHEMBL371512 | 1.00 | GBA1 (1.00) | GBA1FUCA1LMNAAPPSI | |
| SCHEMBL21348880 | 1.00 | GBA1 (1.00) | GBA1FUCA1LMNAAPPSI | |
| SCHEMBL371511 | 1.00 | GBA1 (1.00) | GBA1FUCA1LMNAAPPSI | |
| SCHEMBL14007131 | 1.00 | GBA1 (1.00) | GBA1FUCA1LMNAAPPSI | |
| SCHEMBL15926078 | 1.00 | GBA1 (1.00) | GBA1FUCA1LMNAAPPSI | |
| SCHEMBL10824967 | 1.00 | GBA1 (1.00) | GBA1FUCA1LMNAAPPSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3982996-A | CULTURING | STERLING DRUG INC. (US) | 1976-09-28 | — | — | US | claimed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4170347-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20190309289-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370654-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180320170-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2018-11-08 | — | — | US | disclosed |
| US-9944925-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. | 2018-04-17 | — | — | US | disclosed |
| US-20160186168-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2016-06-30 | — | — | US | disclosed |
| EP-3027754-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | enEvolv, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| US-7988950-B2 | Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (MRI) which contain a chelating moiety with polyhydroxylated substituents | BRACCO IMAGING S.P.A. (IT) | 2011-08-02 | — | — | US | disclosed |
| US-7988950-B2 | Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (MRI) which contain a chelating moiety with polyhydroxylated substituents | BRACCO IMAGING S.P.A. (IT) | 2011-08-02 | — | — | US | disclosed |
| EP-1765812-B1 | CONTRAST AGENTS ENDOWED WITH HIGH RELAXIVITY FOR USE IN MAGNETIC RESONANCE IMAGING (MRI) WHICH CONTAIN A CHELATING MOIETY WITH POLYHYDROXYLATED SUBSTITUENTS | BRACCO IMAGING SPA (IT) | 2009-04-29 | — | — | EP | disclosed |
| EP-1786475-B1 | 1,4-BIS(CARBOXYMETHYL)-6-[BIS(CARBOXYMETHYL)AMINO]-6-METHYL-PERHYDRO-1,4-DIAZEPINE (AAZTA) DERIVATIVES AS LIGANDS IN HIGH RELAXIVITY CONTRAST AGENTS FOR USE IN MAGNETIC RESONANCE IMAGING (MRI) | BRACCO IMAGING SPA (IT) | 2009-04-29 | — | — | EP | disclosed |
| US-20070258905-A1 | Contrast Agents Endowed with High Relaxivity for Use in Magnetic Resonance Imaging (Mri) Which Contain a Chelating Moiety with Polyhydroxylated Substituents | BRACCO IMAGING SPA (IT) | 2007-11-08 | — | — | US | disclosed |
| US-20070258905-A1 | Contrast Agents Endowed with High Relaxivity for Use in Magnetic Resonance Imaging (Mri) Which Contain a Chelating Moiety with Polyhydroxylated Substituents | BRACCO IMAGING SPA (IT) | 2007-11-08 | — | — | US | disclosed |
| US-4307072-A | X-RAY CONTRAST AGENTS | MALLINCKRODT, INC. (US) | 1981-12-22 | — | — | US | disclosed |
| US-4224440-A | NON-IONIC X-RAY CONTRAST AGENTS | MALLINCKRODT, INC. (US) | 1980-09-23 | — | — | US | disclosed |
| US-4109081-A | X-RAY CONTRAST AGENTS | MALLINCKRODT, INC. (US) | 1978-08-22 | — | — | US | disclosed |
| US-3982996-A | CULTURING | STERLING DRUG INC. (US) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258905-A1 | Contrast Agents Endowed with High Relaxivity for Use in Magnetic Resonance Imaging (Mri) Which Contain a Chelating Moiety with Polyhydroxylated Substituents | RXFP1, SLC5A7, SLC40A1 | GBA1 826/4885FUCA1 1745/4885LMNA 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.